Decision Support System (Software) for multi antidiabetic drug therapy use in type 2 diabetes (T2D).
Age ≥18.0 years old at time of consent.
Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months.
Hemoglobin A1c (HbA1c) ≥ 7.0%.
Currently using an approved long-acting insulin for at least 3 months (e.g., insulin glargine, insulin degludec).
Currently using rapid insulin for at least three months (e.g., insulin aspart, insulin lispro, insulin regular).
Currently being treated for a seizure disorder.
Seizure disease
Decompensated cardiac disease
Daniel Chernavvsky, MD
Lead sponsor
University of Virginia
Sponsor institution
University of Virginia
Collaborator